BriaCell Therapeutics Corp. (OTCMKTS:BCTXF – Get Free Report) shares dropped 5.6% during trading on Wednesday . The company traded as low as $2.19 and last traded at $2.19. Approximately 22,628 shares were traded during mid-day trading, an increase of 1,117% from the average daily volume of 1,859 shares. The stock had previously closed at $2.32.
BriaCell Therapeutics Price Performance
The firm has a market cap of $1.73 million, a P/E ratio of -0.58 and a beta of 1.09. The stock has a 50 day moving average of $2.84 and a 200 day moving average of $3.94.
About BriaCell Therapeutics
BriaCell Therapeutics Corp. operates as a clinical-stage biotechnology company that specializes in immunotherapy for advanced breast cancer. It is advancing its targeted immunotherapy program by conducting a Phase I/IIA clinical trial with Bria-IMT in combination with an immune checkpoint inhibitor and a companion diagnostic test, BriaDx, to identify patients to benefit from Bria-IMT.
Featured Stories
- Five stocks we like better than BriaCell Therapeutics
- How Investors Can Find the Best Cheap Dividend Stocks
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is the Hang Seng index?
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Most Volatile Stocks, What Investors Need to Know
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
